NFKB1 and AL amyloidosis: Thalidomide is a for multiple myeloma U.S. Food and Drug Administration (FDA) approved NF-κB modulator that interferes with the NF-κB activation and is currently investigated to reduce urinary complications, a normal tissue complication, upon irradiation of the pelvic region (184).